PSTX News and Press, Poseida Therapeutics Inc. From 08/07/23

Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update PR Newswire $50 million strategic investment validates Poseida's proprietary technology and cell therapy approach and supports strategic and operational plans Implementing ...

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy PR Newswire Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products u...

2023-07-11 15:58:55 ET Summary Poseida Therapeutics has reported Q1 2023 revenues of $10.3 million, a significant increase from $1.4 million in Q1 2022, primarily due to a collaboration with Roche. The FDA has cleared Poseida's Investigational New Drug application for P-CD19CD20-A...

2023-07-05 10:02:39 ET Gainers: Impel Pharmaceuticals ( IMPL ) +32% . Adicet Bio ( ACET ) +18% . C4 Therapeutics ( CCCC ) +17% . NLS Pharmaceutics ( NLSP ) +7% . Poseida Therapeutics ( PSTX ) +4% . Losers: Amneal Pharmaceu...

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies PR Newswire Believed to be the first FDA IND clearance of an allogeneic dual CAR-T therapy targeting CD19 an...

2023-06-26 12:09:08 ET Cell and gene therapy company Poseida Therapeutics ( NASDAQ: PSTX ) said on Monday that it is set to join the broad-market Russell 3000 and small-cap Russell 2000 indexes at the conclusion of the 2023 Russell indexes annual reconstitution. The addit...

Poseida Therapeutics to Join Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 26, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for pati...

Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders PR Newswire SAN DIEGO , June 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patie...

Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day PR Newswire SAN DIEGO , May 23, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatment...

Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis PR Newswire SAN DIEGO , May 22, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advanci...